Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
38 studies found for:    C21005
Show Display Options
Rank Status Study
1 Completed Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
2 Completed
Has Results
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride;   Drug: Atomoxetine Hydrochloride;   Drug: Placebo Comparator
3 Recruiting A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Intervention: Drug: EVP-6124
4 Recruiting A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Chemotherapy;   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab [Herceptin]
5 Active, not recruiting Trastuzumab in Treating Women With Primary Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Procedure: adjuvant therapy
6 Active, not recruiting Eslicarbazepine Acetate Monotherapy Long Term Study
Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
7 Completed A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Condition: Schizophrenia
Interventions: Drug: bitopertin [RO4917838];   Drug: olanzapine;   Drug: placebo
8 Recruiting A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Placebo;   Drug: CP690,550;   Drug: CP-690,550
9 Completed Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
Condition: Carcinoma, Renal Cell
Intervention: Drug: Gemcitabine, Capecitabine and Sorafenib (6 cycles)
10 Completed
Has Results
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate (BIA 2-093);   Drug: Placebo
11 Recruiting Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: CP-690,550
12 Completed A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia
Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: Epoetin alfa
13 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
14 Active, not recruiting A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Condition: Crohn's Disease
15 Enrolling by invitation Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BIIB019 (Daclizumab High Yield Process)
16 Recruiting A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib;   Drug: Placebo
17 Recruiting A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib;   Drug: Placebo
18 Completed A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar;   Drug: Placebo
19 Recruiting A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
20 Completed Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
Condition: Hypertension
Interventions: Drug: Candersartan;   Drug: Nifedipine (Adalat, BAYA1040);   Drug: Nifedipine GITS/Candersartan;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years